RACURA ONCOLOGY LTD — Director's Dealing 2021

Sep 2, 2021

ASX Announcement

Appendix 3Y – Dr John Cullity

3 September 2021 – Race Oncology Limited ("Race") advises that Dr John Cullity, through the holding company Biosynergy Partners Pty Ltd, has sold 61,745 shares for the purposes of covering the costs associated with the exercise of 1,893,939 options as announced on 23 August 2021.

A copy of the Appendix 3Y for Dr Cullity is attached.

-ENDS

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene® (bisantrene dihydrochloride).

Zantrene® is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene® as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers. The Company also has compelling clinical data for the use of Zantrene® as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas.

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development and regulatory approval of Zantrene®.

See more at www.raceoncology.com.

Release authorised by: Media contact:

Phil Lynch, CEO/MD on behalf Jane Lowe of the Race Board of Directors +61 411 117 774

phillip.lynch@raceoncology.com jane.lowe@irdepartment.com.au

Appendix 3Y

Rule 3.19A.2

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Race OncologyLimited
ABN	61 149 318 749

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr JohnCullity
Date of last notice	23 August 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstancesgiving rise to the relevant interest.	1.Craganorig Holdings, LLC –director related entity2.Biosynergy Partners Pty Ltd –director related entity
Date of change	31 August2021, 1 and 2 September 2021
No. of securities held priorto change	1.2,000,000 Options exercisable at $0.23, expiring27/11/2021,subject to vesting conditions.2.5,681,817Ordinary Shares1,000,000 Options exercisableat $0.25, expiring 25/11/2021189,394 Options exercisable at $4.50, expiring 16/5/2022
Class	Ordinary Shares
Number acquired	Nil
Number disposed	2.61,745Ordinary shares
Value/Considerationincludes brokerage/gstNote: If consideration is non-cash, providedetails and estimated valuation	$192,798.78

+ See chapter 19 for defined terms.

No. of securities held afterchange	1.2,000,000 Options exercisable at $0.23, expiring 27/11/2021,subject to vesting conditions.2.5,620,072Ordinary Shares1,000,000 Options exercisableat $0.25, expiring 25/11/2021189,394 Options exercisable at $4.50, expiring 16/5/2022
Nature of changeExample: on-market trade, off-market trade,exercise of options, issue of securities underdividend reinvestment plan, participation inbuy-back	On-market sale of shares to cover the costs of exercise ofoptions.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities towhich interest related prior tochangeNote: Details are only required for a contract in relationto which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and anestimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed	No.
above traded during a +closed periodwhere prior written
clearance was required?
If so, was prior written clearance provided to allow the	N/A
trade to proceed during this period?
If prior written clearance was provided, on what date was	N/A
this provided?

+ See chapter 19 for defined terms.